Open Access<p>Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy</p>
Author(s) -
Urooj Ahmed Khan,
Uzma Parveen,
Nazeer Hasan,
Mohammad Zubair Ahmed,
Suma Saad,
Feroz Ahmad,
Gaurav Jain
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s247196
Subject(s) - pharmacology , chemistry , biocompatibility , sulforhodamine b , medicine , biochemistry , organic chemistry , cytotoxicity , in vitro
Ziprasidone (ZP) is a novel atypical antipsychotic agent effective in the treatment of positive and negative symptoms of schizophrenia with low chances for extrapyramidal side effects (EPs) and cognitive deficits. ZP possesses poor oral bioavailability (~50%), short biological half-life (~2.5 h) and due to extensive first-pass metabolism, a repeated dose is administered which makes the therapy non-adherent, leading to patient non-compliance. Therefore, this is a first report of developing parenteral ZP loaded sustained release phospholipid based phase-transition system (ZP-LPS).